Graduated in 2014 with a degree in Drug Metabolism and Pharmacokinetics from China Pharmaceutical University, under the guidance of Professor Liu Xiaodong, specializing in DMPK research and drug efficacy evaluation for innovative pharmaceuticals.
Engaged Clinical Pharmacology on innovative drugs after graduation, and have served in WuXi AppTec and Jiangsu Hengrui Medicine Co., Ltd successively. Joined Simcere Pharmaceutical Co. Ltd in 2020, responsible for the clinical pharmacology of multiple innovative drugs, participated in the design of Phase I to III clinical studies and clinical registration, and led the completion of multiple clinical pharmacology studies.
Responsible for the clinical pharmacology work of the anti COVID-19 drug Simnotrelvir Tablets/Ritonavir Tablets(co-packaged) and the anti-tumor drug Trilaciclib, providing support from preclinical PCC to IND application, as well as Phase I to III clinical research and NDA application to marketing approval.
临床药理副总监/先声再明
2014年毕业于中国药科大学药物代谢动力学专业，师从刘晓东教授，专注于创新药的DMPK研究和成药性评价；
毕业后一直从事创新药的临床药理研究，先后在药明康德和恒瑞医药任职。
2020年加入先声药业，负责多项创新药的临床药理工作，参与多项创新药的I~III期临床研究设计以及临床注册申请，主导完成多项临床药理研究；
负责抗新冠药物先诺欣以及抗肿瘤药物曲拉西利的临床药理工作，支持从临床前PCC至IND申请以及I~III期临床研究和NDA申报至上市获批。